Category OCUL

http://www.ocutx.com/

Ocular Therapeutix (Nasdaq: $OCUL): Sanofi Rumor, AXPAXLI and the Real Takeover Logic Behind the Wet AMD Story

ocul rumors

Ocular Therapeutix is back in focus after media reports linked Sanofi to a possible takeover approach. According to reports citing French publication La Lettre, Sanofi previously approached Ocular with an offer around $16 per share, Ocular’s board reportedly rejected that initial proposal, and Sanofi may be considering or preparing a higher bid. Neither Ocular Therapeutix nor Sanofi has confirmed a transaction, and that distinction matters. The confirmed foundation of the story is not the takeover rumor; it is AXPAXLI, Ocular’s investigational axitinib intravitreal hydrogel implant, which recently produced positive Phase 3 SOL-1 data in wet age-related macular degeneration.

OCUL Ocular Therapeutix Inc

Daily Hit on Ocular Therapeutix after the latest spike on renewed takeover chatter and ahead of the 52-week phase 3 SOL-1 readout for AXPAXLI (suprachoroidal axitinib). Cash-heavy balance sheet, a single pivotal asset at the centre of the story, and a market now trying to price both M&A optionality and binary clinical risk.